Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Friday, June 21, 2019

Investor Ideas Adds New #Stocks in Biotech (NASDAQ: $PCRX) (NASDAQ: $NGM), Crypto (TSXV: $CSTR.V) & Tech (NYSE: $FVRR), Luxury Brands (NYSE: $RVLV) and Pets (NYSE: $CHWY)

Investor Ideas Adds New #Stocks in Biotech (NASDAQ: $PCRX) (NASDAQ: $NGM), Crypto (TSXV: $CSTR.V) & Tech (NYSE: $FVRR), Luxury Brands (NYSE: $RVLV) and Pets (NYSE: $CHWY)



Point Roberts WA, Delta BC June 21, 2019 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week’s additions to its global stock directories in biotech, tech and cryptom and luxury brands & pets.


This week’s new companies include recent Nasdaq Biotech IPO’s which are involved in pain management, ocular health, biopharmaceuticals and medical devices.  Also new is NervGen Pharma Corp. (TSXV:NGEN.VOTCQX: NGENF) which is involved in the treatment of nerve and spinal cord injuries.

The latest crypto company has one of the world's largest cryptocurrency mining operations, while the newest tech company, Fiverr International Ltd. (NYSE:FVRR) operates an online marketplace worldwide.

The newest luxury brand is REVOLVE GROUP, LLC (NYSE:RVLV) the next-generation fashion retailer for millennial consumers.

Investor Ideas has also added a new section to its luxury brand retail list - pet stocks.  You can see the partial list here https://www.investorideas.com/Luxury-Brand-Retail/Stocks_List.asp and can expect to see more stocks added in the coming weeks.

New Biotech Companies:
NervGen Pharma Corp. (TSXV:NGEN.VOTCQX: NGENFis restoring life's potential by creating innovative solutions for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. The Company also continues to research secondary applications such as multiple sclerosis, stroke, acute myocardial infarction induced arrhythmia ("AMI", commonly known as a heart attack) and other neurodegenerative diseases. NervGen plans to initiate a Phase 1 human clinical trial for its lead compound, NVG-291, in early 2020 under an Investigational New Drug application with the U.S. Food and Drug Administration. NervGen is advancing NVG-291 for the treatment of spinal cord injury as the Company believes this indication is a significant opportunity due to the current lack of non-surgical solutions in the market, the dramatic impact on quality of life and the high cost burden to the healthcare system. The Company believes NVG-291 as a therapy could alleviate or improve upon the symptoms and conditions associated with spinal cord injury and empower these patients to live more active and productive lives.

Pacira BioSciences, Inc. (NASDAQGS: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.  In April 2019, the company acquired the ioverao  system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves.

GUARDION HEALTH SCIENCES, INC (NasdaqCM:GHSI) is an ocular health sciences company that develops, formulates and distributes condition-specific medical foods supported by evidence-based protocols, with an initial medical food product, Lumega-Z, that addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”) and a significant component of functional vision performance. Guardion Health Sciences, Inc. has also developed a proprietary medical device, the MapcatSF®, which accurately measures the macular pigment density, therefore providing the only two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment.
                                                                                                             
NGM BIOPHARMACEUTICALS INC (NasdaqGS:NGM) is a clinical stage biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company leverages its biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable it to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. NGM aspires to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development
                                                                                                             
SILK ROAD MEDICAL INC (NasdaqGM:SILK) is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke.

New Crypto Companies:
CryptoStar Corp. (TSXV: CSTR.V) has one of the world's largest cryptocurrency mining operations with data centres located in the U.S.A., Canada and Iceland. CryptoStar is currently dedicated to further expansion into low cost energy regions in North America and around the globe.



Get more Bitcoin and Blockchain Investor ideas - news, articles and stock directories




New Tech Companies:
Fiverr International Ltd. (NYSE:FVRR) operates an online marketplace worldwide. Its platform enables sellers to sell their services and buyers to buy them. The company's platform includes approximately 200 categories in 8 verticals, including graphic and design, digital marketing, writing and translation, video and animation, music and audio, programming and technology, business, and lifestyle. Its buyers include businesses of various sizes, as well as sellers comprise a group of freelancers and small businesses.

New Luxury Brand Companies:
REVOLVE GROUP, LLC (NYSE:RVLV) is the next-generation fashion retailer for millennial consumers. As a trusted, premium lifestyle brand, and a go-to online source for discovery and inspiration, we deliver an engaging customer experience from a vast yet curated offering totaling over 45,000 apparel, footwear, accessories and beauty styles. Our dynamic platform connects a deeply engaged community of millions of consumers, thousands of global fashion influencers, and more than 500 emerging, established and owned brands. Through 16 years of continued investment in technology, data analytics, and innovative marketing and merchandising strategies, we have built a powerful platform and brand that we believe is connecting with the next generation of consumers and is redefining fashion retail for the 21st century.

New Pet Companies:
Chewy, Inc. (NYSE: CHWY) mission is to be the most trusted and convenient online destination for pet parents everywhere. We believe that we are the preeminent online source for pet products, supplies and prescriptions as a result of our broad selection of high-quality products which we offer at competitive prices and deliver with an exceptional level of care and a personal touch. We continually develop innovative ways for our customers to engage with us and partner with more than 1,600 of the best and most trusted brands in the pet industry to bring a high-bar, customer-centric experience to our customers.

Freshpet, Inc. (NasdaqGM:FRPT) mission is to improve the lives of dogs and cats through the power of fresh, real food. Freshpet foods are blends of fresh meats, vegetables and fruits farmed locally and made at our Kitchens in Bethlehem, PA. We thoughtfully prepare our foods using natural ingredients, cooking them in small batches at lower temperatures to preserve the natural goodness of the ingredients. Freshpet foods and treats are kept refrigerated from the moment they are made until they arrive at Freshpet Fridges in your local market. Our foods are available in select mass, grocery (including online), natural food, club, and pet specialty retailers across the United States, Canada and Europe. From the care we take to source our ingredients and make our food, to the moment it reaches your home, our integrity, transparency and social responsibility are the way we like to run our business.

PetIQ, Inc. (NasdaqGS:PETQ) is a leading, rapidly growing pet health and wellness company.  Through over 60,000 points of distribution across retail and e-commerce channels, PetIQ and VIP Petcare, a wholly-owned subsidiary, have a mission to make pet lives better by educating pet parents on the importance of offering regular, convenient access and affordable choices for pet preventive and wellness veterinary products and services.  PetIQ believes that pets are an important part of the family and deserve the best products and care we can give them.

PetMed Express (NasdaqGS:PETS) Founded in 1996, PetMed Express is America’s Largest Pet Pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs and cats at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.1800petmeds.com

Pets at Home Group, PLC (LSE:PETS.L) the UK’s leading pet care business, providing pet owners with everything they need to be able to look after their pet – from food, toys and bedding, and grooming services, right the way through to first opinion veterinary care and world class specialist veterinary hospitals.

Dechra Pharmaceuticals (LSE:DPH.L) is an international specialist veterinary pharmaceuticals products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

Follow us on Twitter https://twitter.com/Investorideas

To sponsor a daily podcast for the month or to be an expert guest please contact us!

Contact Investorideas.com
800-665-0411









Wednesday, June 19, 2019

#Cannabis and OTC Medications Sector Snapshot-More Health Canada Approval with Rise of Cannabis/Wellness Market (OTCQB: $INNV) (NASDAQ: $NEPT) (OTCQX: $WDDMF) (NASDAQ: $KOOL)


#Cannabis and OTC Medications Sector Snapshot-More Health Canada Approval with Rise of Cannabis/Wellness Market (OTCQB: $INNV) (NASDAQ: $NEPT) (OTCQX: $WDDMF) (NASDAQ: $KOOL)


Point Roberts WA, Delta BC – June 19, 2019 - Investorideas.com, a leading investor news resource covering biotechnology, pharmaceutical and cannabis stocks releases a sector snapshot reporting on how, as the now legalized cannabis industry has gained heavy traction federally with Health Canada approvals, this potentially helps open the doors for other OTC medications and wellness products.

Companies featured  include Innovus Pharmaceuticals, Inc. (OTCQB: INNV), Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT), WeedMD Inc. (TSXV:WMD) (OTCQX:WDDMF) and Cesca Therapeutics (NASDAQ: KOOL).

Innovus Pharmaceuticals, Inc. (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, recently announced that it has made significant progress on the regulatory and manufacturing steps needed to obtain market authorization from Health Canada to commercialize its FlutiCare® brand in Canada. The Company expects to secure the needed market authorization, manufacturing and supply of the product from an existing Canadian manufacturer during the second half of 2019, pending Health Canada approval.  The product is expected to be available as an over the counter drug (“OTC”) in that country and will not require a prescription.


“We are pleased to announce progress relating to our plans to commercialize FlutiCare® in Canada as this is will be our first international market for the product if approved by Health Canada,” said Innovus Pharma CEO, Dr. Bassam Damaj. “In addition to Canada, we are working with the regulatory bodies of several other countries to assess the requirements needed to file for market authorization in those countries.”

In addition to FlutiCare®, the Company recently jointly announced with its former distribution partner, Acerus Pharmaceuticals, Inc., (a Canadian company [“Acerus”]), that it would be receiving back all the rights to its product UriVarx®, approved for the relief of symptoms of overactive bladder and urine incontinency by Health Canada. “Receiving the rights to the product back from Acerus, which allows Innovus Pharma to fully commercialize it under our sales and marketing platform, was the most logical step for us to take to ensure the full market potential of UriVarx® in Canada.  We currently expect additional revenues of at least $1.5 million a year from the sales of the product in Canada versus the $0.5 million recognized for the previous year,” added Dr. Damaj.

“The Company continues to assess the performance of its partners in Canada and around the world and will continue to take steps to ensure that they perform to achieve maximum sales potential of our products. To that effect, the Company will no longer supply Apeaz® to Showcase, Inc., (a Canadian company), as the marketing requirements through their platform as compared to the sales achieved by them from this product were not satisfactory to Innovus Pharma. Under our sales and marketing platform, Apeaz® is now our second-best performing product in Canada that we sell directly there, after Diabasens® and is on track to achieve over $2 million in revenues for 2019,” stated Dr. Damaj.

The Company has 13 products approved and commercialized in Canada including Zestra®, Zestra Glide®, Uxor®, DiabaSens®, Vesele®, RecalMax®, UriVarx®, ProstaGorx®, BH Testosterone®, AllerVarx®, Xyralid® Cream, Xyralid® Suppositories, and Apeaz® and has filed or is in the process of filing for six additional products including, FlutiCare®, PeVarx®, Healthifeet®, Breastlift®, ArthriVarx® and CarvaNum™.

Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT) recently announced that its wholly owned subsidiary, 9354-7537 Quebec Inc. has received a notification letter from Health Canada indicating that all requested license amendments have been approved.

The scope of the amendment received from Health Canada permits expansion of cannabis operation areas to include an additional extraction room where Neptune will perform cold ethanol extraction. Ethanol extraction is faster and more cost effective than the CO2 extraction currently used and will increase Neptune's input capacity from 30,000 kg to 200,000 kg.

The amendment from Health Canada also includes expansion for an encapsulation room where Neptune will produce cannabis oil capsules using the Licaps® technology licensed from Lonza Group AG. The encapsulation equipment is commissioned and ready for commercial operations with a capacity of up to 200 million capsules annually. The Licaps® technology supports differentiated product offerings through its various delivery systems, colors and branding possibilities. Furthermore, this is an effective technology for variable and multiple product formulation runs.

Neptune's Board of Directors recently approved an investment of $7 million to establish additional formulation, manufacturing and packaging infrastructure. This investment will allow Neptune to provide formulation services for new expected product forms such as vape pens, topicals, beverages, sprays, and others. A $4 million investment has also been approved, due to strong customer demand, to increase extraction capacity to a total of 1,500,000 kg, under Neptune's Phase IIIA expansion plans, targeted for completion before the end of calendar year 2019.
With this approval, Neptune is now positioned to submit further license amendments to incorporate the manufacturing of additional product forms, and packaging capabilities, as well as for the Phase IIIA extraction capacity expansion.

Another Cannabis company, WeedMD Inc. (TSXV:WMD) (OTCQX:WDDMF), a federally-licensed producer and distributor of medical-grade cannabis who recently secured Health Canada approval for 27 acres of low-cost, outdoor cultivation on its Strathroy, Ontario property, recently announced that it is the first licensed producer (LP) to be included in Shoppers Drug Mart and TruTrace Technologies’ medical cannabis verification pilot project.

As recently announced by Shoppers and TruTrace at The Second Annual World Cannabis Congress, the Pilot Project is built on TruTrace’s proprietary StrainSecure™ platform, which focuses on testing and verification to confirm the origin, authenticity and quality assurance of cannabis products. Link here to read. WeedMD has been a medical cannabis supplier to Shoppers since February 2019 and was the first licensed producer to partner with TruTrace and utilize the StrainSecure™ platform to register its genetics in late 2018.

“We registered 40 of our proprietary cannabis strains with TruTrace last October, recognizing the importance of strain validation as cannabis products advance through the medical and pharmaceutical channels,” said Keith Merker, CEO of WeedMD. “We’re proud to be the first LP to be included in Shoppers and TruTrace’s recently announced pilot project. Patients and their medical practitioners expect traceability and origin assurance of their cannabis strains as it goes a long way to building continued trust and accountability in our industry.”

ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (NASDAQ: KOOL) and a market leader in automated cellular processing recently announced that it has received Health Canada approval of its next-generation AXP®II system for cord blood processing.

The AXP® II, together with the company's companion, single-use, cell separation set, provides automated, rapid and reproducible harvesting of stem and progenitor cells from collected units of umbilical cord blood in a "functionally-closed" sterile system. The system, which received 510(k) market clearance from the US Food & Drug Administration (FDA) in November 2018, is used by premier public and private cord blood banks worldwide. It provides customers with upgraded functionality, user interface and compatibility with newer operating systems, and features an improved docking station and XpressTRAK® software to maintain compliance with Current Good Manufacturing Practice (cGMP) and Current Good Tissue Practice (cGTP) regulations.

Haihong Zhu, President of ThermoGenesis stated, "Health Canada's approval of the AXP® II - following its approval of the PXP® System earlier this year - marks the achievement of yet another key milestone and should allow us to meaningfully expand our footprint with a best-in-class system that today continues to hold a market-leading position. That said, we look forward to building on our customer base by offering Cord Blood Banks throughout Canada with the ability to undertake cord blood processing with a system that generates mononuclear cell (MNC) recoveries of >90% and CD34+ stem and progenitor cell recoveries of > 95%."

With the current Canadian federal legalization of cannabis and the forthcoming expected regulation updates due this October, both the pharmaceutical and wellness sectors are taking notice and following some of the same paths towards approval in the legal cannabis market. While this may be beneficial to those companies in the cannabis, pharmaceutical and wellness sectors, the real winner will be the Canadian consumer, who will no longer be cornered into having only one option as their medical/health treatment.

Investorideas.com has created a directory of publicly traded cannabis and biotech companies to research as part of its membership. Learn more at https://www.investorideas.com/membership/

About Investorideas.com - News that Inspires Big Investing Ideas

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: this  article featuring INNV is a paid for service on Investorideas.com ( two thousand ) by a third party. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Contact Investorideas.com
800-665-0411


Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories




Friday, June 14, 2019

Investor Ideas Adds New #Stocks in Mining (CSE: $RNR.C), (TSXV: $SOCK.V), Tech (NASDAQ: $APPS), Biotech (NYSE: $PFNX) and Ride Sharing (NYSE: $UBER) (Nasdaq: $LYFT)

Investor Ideas Adds New #Stocks in Mining (CSE: $RNR.C), (TSXV: $SOCK.V), Tech (NASDAQ: $APPS), Biotech (NYSE: $PFNX) and Ride Sharing (NYSE: $UBER) (Nasdaq: $LYFT)




Point Roberts WA, Delta BC June 14, 2019 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week’s additions to its global stock directories in mining, tech, biotech and ride sharing.


New mining companies are all listed on Canadian exchanges (TSX and CSE) and have operations in both Canada and the United States.

The latest tech companies are involved in fintech and business technology, while the newest biotech companies are involved in clinical and commercial stage treatments for unmet patient needs.

Investor Ideas is adding a new section to its automotive stocks list – Ride Sharing Stocks – which will continue to be built up in the coming weeks.  The first additions to this list are the two most well-known ride sharing companies: Uber Technologies, Inc. (NYSE:UBER) and Lyft, Inc. (NasdaqGS:LYFT).

New Mining Companies:
Mariner Resources Corp. (CSE:RNR) is a mineral exploration company focused on the exploration and development of the Silver Dollar Property, located within the Revelstoke Mining Division

Smooth Rock Ventures Corp. (TSXV:SOCK.V)  acquires, explores for, and develops mineral, and oil and gas properties. It has an option to acquire a 100% interest in the Mattagami River zinc property comprising 14 unpatented mining claims located northeast of the town of Kapuskasing, Ontario; and a 33.33% working interest in the Days Chapel enhanced oil recovery project situated in Anderson County, Texas. 

TROUBADOUR RESOURCES INC. (TSXV: TR.VOTCPK: TROUFThe Amarillo Project consists of seven (7) mineral tenures totalling 4,178 hectares and is situated within the heart of a major mining district. The multi-element geochemical signature of the Amarillo Project is consistent with a large multi-phase mineralizing system and is acutely similar to some of the neighbouring mining operations; such as the Brenda Cu-Mo-Ag-Au porphyry mine located 10 kilometres to the north that produced 278,000 tonnes of copper, 66,000 tonnes of molybdenum, 125 tonnes of silver and 2 tonnes of gold over a twenty-year mine life 

New Tech Companies:
Digital Turbine, Inc. (NASDAQ: APPS) innovates at the convergence of media and mobile communications, connecting top mobile operators, OEMs and publishers with app developers and advertisers worldwide. Its comprehensive Mobile Delivery Platform powers frictionless user acquisition and engagement, operational efficiency and monetization opportunities. Digital Turbine's technology platform has been adopted by more than 30 mobile operators and OEMs worldwide, and has delivered more than one billion app preloads for tens of thousands advertising campaigns. The company is headquartered in Austin, Texas, with global offices in Durham, Mumbai, San Francisco, Singapore and Tel Aviv.

MOBI724 Global Solutions Inc. (TSX:MOS.Va global Fintech company, offers a fully integrated suite of multiple Card-Linked Offers and Rewards, Digital Marketing and Business Intelligence and Payment Solutions (including a mobile EMV compliant payment platform), which work with any payment card, on any mobile device and at any Point of Sale. MOBI724 provides turnkey solutions for card associations, card issuers, banks, retailers, manufacturers, offer providers, to create, manage, deliver and track and measure incentive campaigns worldwide in real time. The company captures value from big data to deliver seamless and personalized user experiences for the benefits of all parties in the ecosystem. MOBI724 headquarters are in Montreal, Canada, and the company presently has operations in North and Latin America, the Caribbean and Asia Pacific.

New Biotech Companies:
Pfenex Inc. (NYSE: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, the Company has created an advanced pipeline of potential therapeutic equivalents, novel biologics, vaccine and vaccine components, and biosimilars. The Company’s lead product candidate is PF708, under development as a therapeutic equivalent drug candidate to Forteo® (teriparatide) indicated for the treatment of osteoporosis. In addition, the Company is developing hematology/oncology products, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension, in collaboration with Jazz Pharmaceuticals Ireland Limited (Jazz).  Both PF743 and PF745 are being developed for the treatment of Acute Lymphoblastic Leukemia (ALL). We also use our Pfēnex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccine candidates under development by third parties.

Heron Therapeutics, Inc. (NASDAQ: HRTX) is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.

New Automotive (Ride Sharing) Companies:
Uber Technologies, Inc. (NYSE:UBER) mission is to create opportunity through movement. We started in 2010 to solve a simple problem: how do you get access to a ride at the touch of a button? More than 10 billion trips later, we’re building products to get people closer to where they want to be. By changing how people, food, and things move through cities, Uber is a platform that opens up the world to new possibilities.

Lyft, Inc. (NasdaqGS:LYFTwas founded in 2012, and has over 30 million riders and 2 million drivers. We are singularly focused on improving people’s lives with the world’s best transportation and committed to building reliable, affordable and sustainable transportation.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

Follow us on Twitter https://twitter.com/Investorideas

To sponsor a daily podcast for the month or to be an expert guest please contact us!

Contact Investorideas.com
800-665-0411








Tuesday, June 11, 2019

#Pharma and #Cannabis Stocks Snapshot - (OTCQB: $INNV) (ASX: OCC) (NASDAQ: $PCRX) (TSXV: $HVT.V) (OTCQX: $HRVOF)


#Pharma and #Cannabis Stocks Snapshot - (OTCQB: $INNV) (ASX: OCC) (NASDAQ:  $PCRX) (TSXV: $HVT.V) (OTCQX: $HRVOF)

Muscle and Repair Treatments versus Surgery and how Europe and Global Markets offer New Opportunities

Point Roberts WA, Delta BC – June 11, 2019 - Investorideas.com, a leading investor news resource covering biotechnology and pharmaceutical stocks releases a sector snapshot reporting on the ongoing growth of OTC pain medication due to consumer demand and a move away from traditional surgeries. More companies are taking a global approach and are seeking to gain approval not only in the US, but also European markets moving forward.

According to a market research report published by P&S Intelligence, the chronic pain treatment market is “expected to reach $105.9 billion by 2024. The market growth is primarily driven by the rising prevalence of chronic conditions, surging geriatric population, and increasing government support toward chronic pain management.”

MotleyFool recently discussed the key differences between the United States and European drug markets, specifically focusing on the key differences in drug approval. “The United States and Europe are drugmakers' biggest markets, but just because a drug wins approval in one doesn't mean it will get the nod in the other. Each market has its own system for clinical trials and drug reviews, and there are key differences in commercializing drugs in these regions that investors ought to know about before investing.”

Looking to European markets, Innovus Pharmaceuticals, Inc. (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, recently announced that it has received the CPNP notification number required to commercialize CarvaNum®, its product for muscle recovery, in all 28 member countries of the European Union. This represents the fifth Innovus Pharma product to receive CPNP notification in the European Union so far, the others being Zestra®, Zestra Glide®, Sensum+®, and Diabasens®. The product will be available as an over the counter (“OTC”) or behind the counter product and does not require a prescription.


“We are pleased to announce the receipt of the CPNP in the European Union for CarvaNum®. CarvaNum®’s market for muscle recovery is fairly large in the EU and we look forward to growing it along with our other products in that region,” said Innovus Pharma CEO, Dr. Bassam Damaj.

“We will continue to file for approval for other products in the European Union, as we expect to grow our approved and/or notified product portfolio there in 2019 to also include Vesele®, UriVarx®, Prostagorx®, ArthriVarx®, Trexar® and BH Testosterone®.”

Innovus is also working on filing for CarvaNum® as a homeopathic drug for muscle cramps in the US and Canada.

Orthocell Limited (ASX: OCC) recently provided its first batch of evidence supporting the efficacy of its CelGro™ nerve regeneration platform.

The company published results on the first four patients to complete the clinical trial using CelGro™, with patients experiencing an 83% improvement in muscle power.

Orthocell said it conducted the trial to demonstrate the effectiveness of CelGro™ and confirm that the platform can be used to guide and promote “tensionless nerve regeneration in damaged peripheral nerves of the hand and upper limb.”

If successfully proven, Orthocell plans to market its CelGro™ platform in Europe and other major markets globally. In the US alone, over 20 million people suffer from peripheral nerve injury as a result of acute muscle injuries every year, at an annual cost of approximately US$150 billion (A$213 billion).

Pacira BioSciences, Inc. (NASDAQ: PCRX) recently announced the publication of its multinational Phase 3 study supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable suspension) as a single-injection interscalene brachial plexus nerve block (ISNB) in patients undergoing total shoulder arthroplasty or rotator cuff repair. The results demonstrate that EXPAREL® significantly improved pain control and reduced opioid consumption through 48 hours compared with placebo and a standardized pain management protocol alone. The data, which provided the basis for FDA approval for this indication, was published in Pain Medicine.

“Traditionally, clinicians seeking regional pain control have been forced to choose between single-injection blocks with a duration of efficacy that does not match analgesic requirements or continuous blocks that are long-lasting but hinder patient mobility due to cumbersome catheters and pumps. Results from this study illustrate the clinical effectiveness of interscalene brachial plexus nerve block with EXPAREL®, which provides prolonged pain control in a single dose without the need for additional equipment,” said Manish Patel, orthopedic surgeon at Eastern Virginia Medical School in Franklin, VA who was also a study investigator and is lead author on the publication. “Further, robust pain control coupled with a reduction or total elimination of opioid requirements, as EXPAREL® demonstrated in this study, are two critical factors toward the increasing clinical goal of moving inpatient procedures to an outpatient setting.”

This uptrend in pain management treatment is also attracting outside interest from the Cannabis sector as Harvest One Cannabis Inc (TSXV;HVT) (OTCQX:HRVOF) recently announced that it has entered into a definitive agreement to acquire Delivra Corp. for C$19 million, in a stock deal to strengthen its medical and wellness division.

Harvest One's acquisition of Delivra furthers the company's health, wellness, and self-care strategy by adding LivRelief™ to its medical and wellness portfolio. Delivra’s LivRelief™ brand produces a variety of topicals and creams with existing distribution channels across Canada. This will well position Harvest One for the time when cannabis-infused products are legalized in Canada, around Fall of 2019.

"The acquisition of Delivra by Harvest One puts further emphasis on the Harvest One goal of being a leading house of brands in the global health, wellness, and self-care sector,” said Harvest One CEO, Grant Froese. “The addition of LivRelief™, which is already on retail shelves across Canada, will give Harvest One a head start for cannabis-infused products in Canada.”

Though many tend to look at the US as the largest market in dollar terms, the European market is still significant with more than 741 million people living there, a fact many of these OTC pain medication companies are taking into consideration when looking to maximize exposure and company revenues moving forward. OTC pain medication is showing impressive gains, but this is a global market moving forward and the companies who gain approval in both markets are hoping to gain a competitive advantage.

Visit the Investorideas.com biotech and pharma stock directory at Investorideas.com

About Investorideas.com - News that Inspires Big Investing Ideas

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: this  article featuring INNV is a paid for service on Investorideas.com ( two thousand ) by a third party. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Contact Investorideas.com
800-665-0411


Get more Biotech Investor Ideas – news, articles and stock directories